Moderator: Catarina Madeira Director, MIT Startup Exchange
Know What Your Model Does Not Know Stewart Jamieson Head of Technology, Themis AI
Looking for 10 Startups to present during Startup Lighting Talks and participate at the lunch Exhibit on April 4, 2023 at the 2023 MIT Health Science Technology Conference.
Non-Invasive Biomarker Measurement Using Sweat
This conference will explore new or improved therapeutic approaches for finding cures for diseases which traditionally have been difficult to treat. This includes technologies for optimizing treatments and monitoring efficacy based on insights into cell and tissue state, circuitry, behavior, function, and responsiveness in normal and disease states, biomarker detection, better methods to predict and track efficacy, and enhanced manufacturing capabilities.
Takeda is looking for new approaches and technologies that can help them address challenges/opportunities in gastroenterology, oncology, neuroscience and rare genetic & hematology.
AI Driven Bloodless Blood Tests Sean (Shunsuke) Matsuoka, Co-Founder & COO, GPx GPx: https://gpx.ai/
In an aging society, the number of heart failure patients is increasing, making the prevention of readmissions and reduction of medical costs critical issues. Remote monitoring using invasive implantable devices has proven effective in reducing heart failure readmissions, but its use remains limited.
To address this, GPx has developed an algorithm that non-invasively predicts signs of heart failure exacerbation. This algorithm was created using clinical trial data from monitoring 245 heart failure patients over 6 months to a year at eight facilities, including the Mayo Clinic in the U.S. The algorithm links digital biomarker data with vital blood tests (NT-proBNP and creatinine) to achieve high-precision prediction and early medical intervention.
Additionally, with a grant of 1.2 billion yen provided through AMED, we are collaborating with the National Cerebral and Cardiovascular Center (Dr. Chisato Izumi) to conduct a clinical trial involving 400 patients starting April 2025. The trial will be conducted at the National Cerebral and Cardiovascular Center, Kyoto University, Kobe University, and Kochi University.
Furthermore, at this year's MIT Japan Conference, we will unveil a groundbreaking point-of-care (POC) potassium testing device for the first time. At the conference, we aim to explore the feasibility of applying our technology to other conditions (such as kidney failure, pulmonary arterial hypertension, and cardio-oncology) and to assess the potential for providing algorithm-based services for heart failure patients within Japan.
Sanjay Manandhar, Aerva Founder & CEO